Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

University of Maryland, Baltimore hosts first national conference on oral and systemic health

By hosting the first national conference on oral and systemic health in Baltimore on Dec. 10, the University of Maryland, Baltimore (UMB) took another major step toward true interprofessional health care education, says Jay A. Perman, MD, president of the University.

19 Dec 2012

Arthritis, rheumatism and total joint arthroplasty: an interview with Dr Ravi and Dr Hawker

Arthritis translates to “joint inflammation.” The most common form of arthritis is osteoarthritis (OA), which affects 12-15% of North Americans over the age of 60, and will increase in prevalence as our population ages.

19 Dec 2012

Ceramic-on-ceramic hips good option for juvenile arthritis

Study results suggest that ceramic-on-ceramic artificial hip joints offer a better medium-term prognosis than metal- or ceramic-on-polyethylene joints for children with juvenile idiopathic arthritis.

18 Dec 2012

Osteoporosis screening: an interview with Professor Cyrus Cooper

Osteoporosis is defined as a reduction in bone mass coupled with micro-architectural deterioration of bone tissue which predisposes to fractures. Osteoporosis manifests through an increased risk of fracture, and age-related fractures are a major public health problem.

17 Dec 2012

Surgery poses cardiac risk to lupus women

Women with systemic lupus erythematosus are at significantly increased risk for short-term perioperative adverse cardiovascular events, find researchers.

17 Dec 2012

Lexicon receives FDA Fast Track status for development of LX1033 for irritable bowel syndrome

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received "Fast Track" status from the U.S. Food and Drug Administration for the development of LX1033, an orally-delivered small molecule drug candidate for diarrhea-predominant irritable bowel syndrome (IBS-d).

17 Dec 2012

CEL-SCI net loss decreases to $17.6 million for fiscal year 2012

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2012.

14 Dec 2012

SLU researchers to study physiological and biochemical functions in lupus

Two researchers at Saint Louis University's division of rheumatology in the department of internal medicine have been awarded a $1.8 million NIH grant to study the physiological and biochemical functions in lupus, an autoimmune disease, and develop possible new medications for its treatment.

14 Dec 2012

Amgen declares $0.47 per share dividend for first quarter 2013

Amgen announced that its Board of Directors today declared a $0.47 per share dividend for the first quarter of 2013.

14 Dec 2012

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).

13 Dec 2012

Health systems must be more ‘adherence-friendly’

Heath system strategies must be appropriately designed to help narrow persistent racial/ethnic gaps in the use of antihypertensive therapy, say researchers.

13 Dec 2012

Heartbeat Experts announces increased revenue and expanded clients in emerging markets

Heartbeat Experts, the global leader in stakeholder management solutions for the life sciences industry, announced today increased revenue and expanded clients across Brazil, Russia, China, India and Korea. Heartbeat Experts' reported combined revenue from these markets grew 50% in the third quarter of 2012.

13 Dec 2012

Patients with multiple sclerosis have low levels of Egr2/3 protein in T lymphocytes

Researchers from Queen Mary, University of London have discovered that two proteins which are believed to play a key role in controlling the body's immune response are found in lower levels in T lymphocytes from patients with multiple sclerosis (MS).

13 Dec 2012

Dantrolene may help combat Duchenne muscular dystrophy in boys

Drugs are currently being tested that show promise in treating patients with Duchenne muscular dystrophy (DMD), an inherited disease that affects about one in 3,600 boys and results in muscle degeneration and, eventually, death.

13 Dec 2012

Takeda, Lundbeck announce FDA acceptance of vortioxetine NDA submission

Takeda Global Research & Development Center, Inc., (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing their submission of a New Drug Application (NDA) for vortioxetine for the treatment of major depressive disorder (MDD) in adult patients.

13 Dec 2012

Moximed commences KineSpring System clinical trial in knee osteoarthritis

Moximed, Inc. announced today that the KineSpring System, an implantable medical spring that works by unloading the weight on the diseased knee joint, has been successfully implanted in the first patient enrolled in its US clinical study, SOAR.

11 Dec 2012

Lenalidomide effective alternative in lupus

The thalidomide derivative, lenalidomide, is a “safe” and effective treatment in refractory cutaneous lupus erythematosus patients, although three-quarters of patients experience clinical relapse after the drug is withdrawn, say Spanish researchers.

11 Dec 2012

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

11 Dec 2012

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced new data from its ongoing Phase 1, open-label, dose-escalation trial of IPI-145, the company's potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with advanced hematologic malignancies.

11 Dec 2012

CYP2J2 implicated in preeclampsia

Study findings suggest that uteroplacental cytochrome P450 subfamily 2J polypeptide 2 overexpression contributes to preeclampsia.

10 Dec 2012

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

University of Maryland, Baltimore hosts first national conference on oral and systemic health

Arthritis, rheumatism and total joint arthroplasty: an interview with Dr Ravi and Dr Hawker

Ceramic-on-ceramic hips good option for juvenile arthritis

Osteoporosis screening: an interview with Professor Cyrus Cooper

Surgery poses cardiac risk to lupus women

Lexicon receives FDA Fast Track status for development of LX1033 for irritable bowel syndrome

CEL-SCI net loss decreases to $17.6 million for fiscal year 2012

SLU researchers to study physiological and biochemical functions in lupus

Amgen declares $0.47 per share dividend for first quarter 2013

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

Health systems must be more ‘adherence-friendly’

Heartbeat Experts announces increased revenue and expanded clients in emerging markets

Patients with multiple sclerosis have low levels of Egr2/3 protein in T lymphocytes

Dantrolene may help combat Duchenne muscular dystrophy in boys

Takeda, Lundbeck announce FDA acceptance of vortioxetine NDA submission

Moximed commences KineSpring System clinical trial in knee osteoarthritis

Lenalidomide effective alternative in lupus

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

CYP2J2 implicated in preeclampsia

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in